CLINICAL_TRIALS
trial_result
· 2021-04-12
Clinical Trial Update: Long-Term Study of MP-214 in Patients With Schizophrenia [Phase 2, Phase 3]
Summary
This document reports the completion of a long-term Phase 2/3 trial evaluating MP-214 for schizophrenia, with results posted on 2021-04-12.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tanabe Pharma Corporation | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-04-12